Jacobio Pharmaceuticals Group Co., Ltd.

SEHK:1167 Lagerbericht

Marktkapitalisierung: HK$1.5b

Jacobio Pharmaceuticals Group Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Jacobio Pharmaceuticals Group has been growing earnings at an average annual rate of 28.7%, while the Biotechs industry saw earnings growing at 31.7% annually. Revenues have been declining at an average rate of 79.9% per year.

Wichtige Informationen

28.7%

Wachstumsrate der Gewinne

53.7%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie11.0%
Wachstumsrate der Einnahmen-79.9%
Eigenkapitalrendite-39.9%
Netto-Marge-1,560.9%
Letzte Ertragsaktualisierung30 Jun 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

May 31
Most Shareholders Will Probably Agree With Jacobio Pharmaceuticals Group Co., Ltd.'s (HKG:1167) CEO Compensation

Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

May 29
Is Jacobio Pharmaceuticals Group (HKG:1167) Using Debt Sensibly?

We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

May 10
We're Hopeful That Jacobio Pharmaceuticals Group (HKG:1167) Will Use Its Cash Wisely

Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

Aug 26
Time To Worry? Analysts Are Downgrading Their Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Outlook

We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

Jul 29
We're Not Very Worried About Jacobio Pharmaceuticals Group's (HKG:1167) Cash Burn Rate

We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

Apr 29
We Think Jacobio Pharmaceuticals Group (HKG:1167) Can Afford To Drive Business Growth

What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Mar 21
What Percentage Of Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) Shares Do Insiders Own?

Aufschlüsselung der Einnahmen und Ausgaben

Wie Jacobio Pharmaceuticals Group Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.


Gewinn- und Umsatzhistorie

SEHK:1167 Einnahmen, Ausgaben und Erträge (CNY Millions)
DatumEinnahmenUmsatzAllgemeine und VerwaltungskostenF&E-Ausgaben
30 Jun 2423-36244350
31 Mar 2443-36145361
31 Dec 2364-35947372
30 Sep 2372-38545420
30 Jun 2381-41043468
31 Mar 2389-39143457
31 Dec 2296-37243446
30 Sep 22123-33246391
30 Jun 22150-29249336
31 Mar 22151-29747308
31 Dec 21153-30145281
30 Sep 21348-57052259
30 Jun 21544-83960237
31 Mar 21515-1,17757211
31 Dec 20486-1,51454186
30 Sep 20243-1,29865171
30 Jun 200-1,08277156
31 Mar 200-75374147
31 Dec 190-42571139

Qualität der Erträge: 1167 is currently unprofitable.

Wachsende Gewinnspanne: 1167 is currently unprofitable.


Analyse von freiem Cashflow und Gewinn


Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: 1167 is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.

Beschleunigtes Wachstum: Unable to compare 1167's earnings growth over the past year to its 5-year average as it is currently unprofitable

Erträge im Vergleich zur Industrie: 1167 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.5%).


Eigenkapitalrendite

Hohe Eigenkapitalrendite: 1167 has a negative Return on Equity (-39.92%), as it is currently unprofitable.


Kapitalrendite


Rendite auf das eingesetzte Kapital


Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren